

Eugia - Recall of acyclovir injection

- On September 27, 2022, <u>Eugia announced</u> a voluntary recall of one lot of <u>acyclovir sodium</u> injection to the consumer level due to a product complaint for the presence of a dark red, brown and black particulate inside the vial.
 - Clinical Services did not identify any impacted members thus notifications will not be sent.
 - Other acyclovir injection products made by Eugia are available for use.
- The recalled lot was distributed June 8, 2022, through June 13, 2022.

| Product Description | NDC# | Lot# (Expiration Date) |
|--|--------------|------------------------|
| Acyclovir sodium injection 500 mg per 10 mL (50 mg/mL), 10 mL single dose vial | 55150-154-10 | AC22006 (8/2023) |

- The administration of an intravenous product containing particulates has the potential to result in inflammation, allergic reactions, or circulatory system complications which could be lifethreatening.
- Acyclovir injection is indicated for the treatment of herpes simplex infections in immunocompromised patients, initial episodes of herpes genitalis, herpes simplex encephalitis, neonatal herpes infections, and varicella-zoster infections in immunocompromised patients.
- To date, Eugia has not received reports of any adverse events or identifiable safety concerns attributed to the product consumed for this recalled lot.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine
 the product immediately. Contact Qualanex by phone at 1-888-280-2046 or email
 recall@qualanex.com for return information.
- Patients should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled products.
- Anyone with questions may contact the Eugia Drug Safety Department by phone at 1-866-850-2876 or email pvg@aurobindousa.com for more information.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.